$3.00-land the week after?
A Phase2 CLR131 clinical trial update will put CLRB THERE OR HIGHER FROM WHAT I hear.
This stock is a hold (and a buy) from what I read.
Today's PR is a game changer!
ESPECIALLY THIS PART:
"...Utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the company’s PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells.
Market Data 
Markets 
AI
